細胞名稱： 人結腸腺癌細胞（STR鑒定正確）

細胞簡稱： SW480

細胞別稱： SW-480; SW 480; SW480E；sw480細胞

貨號：TCH-C348

規格： 1×10?cells/T25培養瓶

價格：1400元 (干冰運輸需另加200元干冰費)

種屬來源：人

組織來源：結腸

特征：結腸腺癌

細胞形態：上皮細胞樣

生長特性：貼壁生長

培養體系：L-15+10%FBS+1%P/S

配套培養基貨號：TCH-G348

傳代比例：1:3-1:6，每2-3天換液一次

傳代周期：48-72 h

培養條件：氣相：空氣，溫度：37℃

凍存條件：60%基礎培養基+30%FBS+10%DMSO，液氮儲存

質量檢測：細菌、真菌、支原體檢測均為陰性

   sw480細胞源自一位51歲白人男性的原位直腸腺癌，而SW620源自同一病人一年后的淋巴結轉移灶。該細胞CSAp和直腸抗原3陰性；角蛋白陽性；p53基因第273位密碼子的G→A突變引起Arg→His替代，309位密碼子的C→T突變導致Pro→Ser替代；細胞p53蛋白表達水平升高；癌基因c-myc、K-ras、H-ras、N-ras、myb、sis和fos的表達呈陽性；未檢測到癌基因N-myc的表達；不表達Matrilysin（一種與腫瘤侵襲相關的金屬蛋白酶）。有報道稱該細胞表達GM-CSF。

  sw480細胞 L-15空氣培養注意要點：

1. 空氣培養注意要點： 

a) 人結腸腺癌細胞（SW480）使用L15空氣培養基。 L-15 采用磷酸鹽和游離氨基酸而非進行緩沖。這種培養基適用 于支持非 CO2 平衡環境中的細胞生長。在使用該培養體系時，須將培養 箱的二氧化碳濃度調節至“0"（維持空氣培養狀態），如果通入5%二氧化 碳通過培養基對細胞產生毒性。

 b) 如您沒有無空氣培養箱，可選擇使用不透氣培養瓶（密封瓶蓋）培養該 細胞，并將瓶蓋擰緊，每次操作時開蓋短時間接觸到的二氧化碳不影響該細胞正常培養。

         圖示：密封瓶蓋培養瓶（左）和透氣瓶蓋培養瓶（右）

 注意：可以選用 SW480細胞專用培養基（即用型培養基）： 已添加血清和雙抗等成分，可直接用于培養SW480細胞。

參考文獻：

"Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed:

Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927

Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092

Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460

Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845

Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501

Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289

Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086

Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224

Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282"